Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(4.33)
# 391
Out of 5,090 analysts
54
Total ratings
36.59%
Success rate
44.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $66 → $75 | $27.87 | +169.11% | 2 | Nov 13, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $10.60 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $68.14 | +29.16% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $18.83 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $45.35 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $71.53 | +34.21% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $11.30 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $220.51 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $12.18 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $8.31 | - | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $18.86 | -31.00% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.54 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $58.85 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $100.48 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.43 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.88 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $40.24 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $181.82 | +60.60% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $457.26 | -19.08% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.44 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.64 | - | 1 | May 30, 2017 |
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $66 → $75
Current: $27.87
Upside: +169.11%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $10.60
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $68.14
Upside: +29.16%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.83
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $45.35
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $71.53
Upside: +34.21%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $11.30
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $220.51
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $12.18
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.31
Upside: -
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $18.86
Upside: -31.00%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.54
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $58.85
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $100.48
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.43
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.88
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $40.24
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $181.82
Upside: +60.60%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $457.26
Upside: -19.08%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.44
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.64
Upside: -